Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9189085 | 0.91 | IDO1 (0.48) | TSHRMAPK1HIF1ATDP1L3MBTL1 | |
| SCHEMBL96816 | 0.75 | ADRB2 (0.50) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL11015372 | 0.75 | ADRB2 (0.50) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL4433661 | 0.75 | BRD4 (0.42) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL8075817 | 0.75 | TSHR (0.41) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL8909503 | 0.74 | LMNA (0.48) | TDP1LMNAHPGDALDH1A1HDAC4 | |
| SCHEMBL9181782 | 0.74 | ESR1 (0.46) | TSHRHIF1ATDP1LMNAHPGD | |
| SCHEMBL7825067 | 0.74 | ALDH1A1 (0.60) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL3719325 | 0.74 | TSHR (0.44) | TSHRMAPK1HIF1ATDP1LMNA | |
| SCHEMBL11798306 | 0.72 | ALDH1A1 (0.41) | TSHRMAPK1HIF1ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | claimed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | claimed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| US-5607931-A | AMIDES | SCHERING CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5149709-A | Treatment of atherosclerosis | SCHERING CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-3974162-A | 4-Pyrimidinylthioacetic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
| US-3940394-A | ANTILIPEMIC | SANTILLI ARTHUR A | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | BDKRB1, BDKRB2, HPGDS | TSHR 3983/4885MAPK1 1063/4885HIF1A 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.